{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-216763","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2026-05-11T20:09:09+00:00","discovered_at":"2026-05-11T20:11:00.398083+00:00","generated_at":"2026-05-11T22:28:27.298524+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Metagenomi reports $140.2M cash; MGX-001 IND on track for Q4 2026","bullets":["Cash, equivalents and marketable securities of $140.2M at March 31, 2026; runway through Q4 2027.","MGX-001 for hemophilia A: regulatory submission including IND planned for Q4 2026, first-in-human trials in 2027.","Kapil Saxena, MD, appointed to lead clinical development for MGX-001; prior roles at Autolus, Bayer, Daiichi Sankyo.","R&D expenses $19.3M in Q1 2026 (vs $25.1M Q1 2025); G&A $6.5M (vs $6.8M).","Nature publication on compact CRISPR nuclease MG119-28 with enhanced editing efficiency."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-216763","json":"https://secwatch.observer/filing/0001193125-26-216763.json","markdown":"https://secwatch.observer/filing/0001193125-26-216763.md","text":"https://secwatch.observer/filing/0001193125-26-216763.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526216763/0001193125-26-216763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526216763/mgx-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:28:27.298524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}